Ovid Therapeutics Inc. OVID 深 滬
已收盤 12-12 16:00:00 美东时间
1.64
-0.010
-0.61%
華盛通- 最 高1.71
- 今 開1.69
- 成交量 88.61万股
- 最 低 1.61
- 昨 收 1.65
- 總市值 1.17亿
- 52周最高 2.01
- 市盈率 靜 --
- 換手率 1.24%
- 52周最低 0.2425
- 委 比 -80.25%
- 總股本 7121.24万
- 歷史最高 15.89
- 量 比 0.59
- 振 幅 6.06%
- 歷史最低 0.2425
- 每 手 1
- 風險率 0.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
12-12 10:24
Ovid Therapeutics Stockholders Approve Key Proposals
Ovid Therapeutics ( ($OVID) ) has issued an announcement. On December 11, 2025,...
12-12 03:17
Roth Capital Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $3
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $3.
12-11 20:57
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
Ovid Therapeutics任命Petra Kaufmann博士为首席医疗官，负责领导临床、医学和监管战略。Kaufmann博士拥有丰富的CNS药物开发经验，曾在Vigil Neuroscience、Affinia Therapeutics和Novartis Gene Therapies担任重要职位，并在NIH推动罕见病研究。她的加入将加强Ovid的研发能力，推动其GABA-AT抑制剂OV329和KCC2激活剂的开发。Kaufmann博士表示，期待与Ovid团队合作，为患者带来创新疗法。
12-02 12:00
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
HC Wainwright & Co. Maintains Buy on Ovid Therapeutics, Raises Price Target to $2
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and raises the price target from $1.5 to $2.
11-24 19:42
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Meg Alexander appointed CEO of Ovid Therapeutics effective January 1, 2026, succeeding Dr. Jeremy M. Levin, who transitions to Executive Chairman. The company reported positive Phase 1 results for OV329, a next-generation GABA-aminotransferase inhibitor, supporting its advancement to Phase 2 studies. OV329 data will be presented at the 2025 American Epilepsy Society meeting. Ovid’s KCC2 activator portfolio is progressing, with OV350 expected to r...
11-12 12:00
NUTEX HEALTH PROVIDES CORPORATE UPDATE
Significant Year-over-Year Growth in Patient Volume and Cash Collections HOUSTON, Oct. 20, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physicia...
10-20 17:30
GALIANO GOLD PROVIDES NOTICE OF THIRD QUARTER 2025 RESULTS
VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ - Galiano Gold Inc. ("Galiano" or the "Company") (TSX: GAU) (NYSE American: GAU) is pleased to announce it will release its third quarter ("Q3") 2025...
10-08 20:30
